# P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management

## TL;DR

A new treatment called P3-GemOx shows better results than an existing therapy for a rare type of lymphoma called NK/T-cell lymphoma.

## Contribution

The P3-GemOx regimen is introduced as a more effective immunochemotherapy option for advanced NK/T-cell lymphoma.

## Key findings

- All patients treated with P3-GemOx achieved a response, with 100% overall response rate.
- No patients in the PP-GemOx group underwent hematopoietic stem cell transplantation, while seven did in the P3-GemOx group.
- Adverse events in the P3-GemOx regimen were manageable and resolved.

## Abstract

Natural killer/T-cell lymphoma (NKTL) is a rare disease that shows suboptimal responses to existing therapies. This study reports the efficacy of the P3-GemOx regimen compared to the traditional PP-GemOx regimen in advanced NKTL.

Eleven patients received the P3-GemOx regimen [mitoxantrone hydrochloride liposome (Plm60) combined with PP-GemOx (anti-PD-1 antibody, pegaspargase, gemcitabine, and oxaliplatin)] every 3–4 weeks, with a median of 3 cycles (range: 1–4). Another eleven patients received the PP-GemOx regimen every 3–4 weeks, with a median of 4 cycles (range: 2–6). Treatment response was assessed using 18F-FDG-PET with CT or MRI.

All patients treated with P3-GemOx responded, with nine achieving complete remission (CR) and two partial remission (PR), yielding an overall response rate (ORR) of 100%. Seven of these patients underwent hematopoietic stem cell transplantation (HSCT). In the PP-GemOx group, the ORR was 63.6%, and no patients underwent HSCT. All adverse events were manageable and resolved.

The P3-GemOx regimen demonstrates superior efficacy over the PP-GemOx regimen in advanced NKTL.